SpringerLink
Log in

Blood and Marrow Transplantation

  • Chapter
Transplantation Surgery

Part of the book series: Springer Specialist Surgery Series ((SPECIALIST))

  • 229 Accesses

Abstract

In the early days of blood and marrow transplantation (BMT), the rationale for the procedure was to administer high doses of chemotherapy or radiation therapy (or both) to patients in an attempt to eradicate their underlying disease and then rescue them with blood or marrow progenitors to shorten the period of cytopenias after such high-dose therapy. Although this principle is still pertinent today, new knowledge of the immune system has extended our understanding of how BMT can treat human disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

eBook
GBP 9.99
Price includes VAT (United Kingdom)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Thomas ED. The Nobel Lectures in Immunology. The Nobel Prize for Physiology or Medicine, 1990. Bone marrow transplantation–past, present and future. Scand J Immunol 1994; 39: 339–45.

    Google Scholar 

  2. Szilvassy SJ, Hoffman R. Enriched hematopoietic stem cells: basic biology and clinical utility. Biol Blood Marrow Transplant 1995; 1: 3–17.

    PubMed  CAS  Google Scholar 

  3. To LB, Haylock DN, Simmons PJ, et al. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233–58.

    PubMed  CAS  Google Scholar 

  4. Anderlini P, Korbling M. The use of mobilized peripheral blood stem cells from normal donors for allografting. Stem Cells 1997; 15: 9–17.

    Article  PubMed  CAS  Google Scholar 

  5. Cairo MS, Wagner JE. Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood 1997; 90: 4665–78.

    PubMed  CAS  Google Scholar 

  6. Rowe JM, Ciobanu N, Ascensao J, et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group. Ann Intern Med 1994; 120: 143–58.

    PubMed  CAS  Google Scholar 

  7. Huntly BJ, Franklin IM, Pippard MJ. Unrelated bone-marrow transplantation in adults. Blood Rev 1996; 10: 220–30.

    Article  PubMed  CAS  Google Scholar 

  8. Gulati SC, Romero CE, Ciavarella D. Is bone marrow purging proving to be of value? Oncology (Huntington) 1994; 8: 19–24.

    CAS  Google Scholar 

  9. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–8.

    PubMed  CAS  Google Scholar 

  10. Bearman SI, Anderson GL, Mori M, et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729–36.

    PubMed  CAS  Google Scholar 

  11. Clark JG, Hansen JA, Hertz MI, et al. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993; 147: 1601–6.

    PubMed  CAS  Google Scholar 

  12. Atkinson K. Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 1990; 5: 209–26.

    PubMed  CAS  Google Scholar 

  13. Wingard JR. Infections in allogeneic bone marrow transplant recipients. Semin Oncol 1993; 20 (Suppl. 6): 80–7.

    PubMed  CAS  Google Scholar 

  14. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fiuconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–51.

    Article  PubMed  CAS  Google Scholar 

  15. Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood 1994; 83: 2392–8.

    PubMed  CAS  Google Scholar 

  16. Antin JH, Ferrara JI,. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964–8.

    PubMed  CAS  Google Scholar 

  17. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855–64.

    Article  PubMed  CAS  Google Scholar 

  18. Lazarus HM, Vogelsang GB, Rowe JM. Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplantation 1997; 19: 577–600.

    Article  PubMed  CAS  Google Scholar 

  19. Sullivan KM, Mori M, Sanders J, et al. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant 1992; 10 (Suppl. 1): 127–34.

    PubMed  Google Scholar 

  20. Schmitz N, Gratwohl A, Goldman JM. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders. Current practice in Europe in 1996 and proposals for an operational classification. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17: 471–7.

    PubMed  CAS  Google Scholar 

  21. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217–23.

    Article  PubMed  CAS  Google Scholar 

  22. Harousseau J-L, Cahn J-Y, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997; 90: 2978–86.

    PubMed  CAS  Google Scholar 

  23. Burnett AK, Goldstone AH, Stevens RMF, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 1998; 351: 700–8.

    Article  PubMed  CAS  Google Scholar 

  24. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–56.

    Article  PubMed  CAS  Google Scholar 

  25. Woods WG, Neudorf S, Gold S, et al. Aggressive post-remission (REM) chemotherapy is better than autologous bone marrow transplantation (BMT) and allogeneic BMT is superior to both in children with acute myeloid leukemia (AML) (abstract). Proc Am Soc Clin Oncol 1996; 15: 368.

    Google Scholar 

  26. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 1996; 334: 1428–34.

    Article  PubMed  CAS  Google Scholar 

  27. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992; 10: 1723–9.

    PubMed  CAS  Google Scholar 

  28. Petersen FB, Lynch MH, Clift RA, et al. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 1993; 11: 1353–60.

    PubMed  CAS  Google Scholar 

  29. Miller CB, Rowlings PA, Jones RJ, et al. Autotransplants for acute myelogenous leukemia (AML): effect of purging with 4-hydroperoxycyclophosphamide (4HC) (abstract). Proc Am Soc Clin Oncol 1996; 15: 338.

    Google Scholar 

  30. Busca A, Anasetti C, Anderson G, et al. Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. Blood 1994; 83: 3077–84.

    PubMed  CAS  Google Scholar 

  31. Ringdén O, Labopin M, Gluckman E, et al. Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Bone Marrow Transplant 1997; 19: 963–8.

    Article  PubMed  Google Scholar 

  32. Clift RA, Buckner CD. Marrow transplantation for acute myeloid leukemia. Cancer Invest 1998; 16: 53–61.

    Article  PubMed  CAS  Google Scholar 

  33. Anderson JE. Stem cell transplantation for myelodysplasia. In: Hematology 1997, The Education Program of the American Society of Hematology, 1997; 166–70.

    Google Scholar 

  34. Barrett AJ, Horowitz MM, Pollock BH, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994; 331: 1253–8.

    Article  PubMed  CAS  Google Scholar 

  35. Sebban C, Lepage E, Vernant J-P, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. J Clin Oncol 1994; 12: 2580–7.

    PubMed  CAS  Google Scholar 

  36. Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995; 86: 1619–28.

    PubMed  CAS  Google Scholar 

  37. Fière D, Lepage E, Sebban C, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol 1993; 11: 1990–2001.

    PubMed  Google Scholar 

  38. Zhang M-J, Hoelzer D, Horowitz MM, et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med 1995; 123: 428–31.

    PubMed  CAS  Google Scholar 

  39. Lazarus HM, Rowe JM. Bone marrow transplantation for acute lymphoblastic leukemia (ALL). Med Oncol 1994; 11: 75–88.

    Article  PubMed  CAS  Google Scholar 

  40. Druker BJ, Talpaz M, Resta D, et al. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia (abstract). Blood 1999; 94: 368a.

    Google Scholar 

  41. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036–43.

    PubMed  CAS  Google Scholar 

  42. Ringden O, Remberger M, Ruutu T, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93: 2196–2201.

    PubMed  CAS  Google Scholar 

  43. Lee SJ, Kuntz KM, Horowitz MM, et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med 1997; 127: 1080–8.

    PubMed  CAS  Google Scholar 

  44. Kantarjian HM, O’Brien S, Anderlini P, et al. Treatment of myelogenous leukemia: current status and investigational options. Blood 1996; 87: 3069–81.

    PubMed  CAS  Google Scholar 

  45. Soll E, Massumoto C, Clift RA, et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995; 86: 4667–73.

    PubMed  CAS  Google Scholar 

  46. Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 1996; 124: 311–15.

    PubMed  CAS  Google Scholar 

  47. Khouri IF, Przepiorka D, van Besien K, et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 1997; 97: 466–73.

    Article  PubMed  CAS  Google Scholar 

  48. Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748–58.

    PubMed  CAS  Google Scholar 

  49. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–92.

    PubMed  CAS  Google Scholar 

  50. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 333: 1540–5.

    Article  PubMed  CAS  Google Scholar 

  51. Vose JM. High-dose chemo/radiotherapy and HSC transplantation for non-Hodgkin’s lymphoma. In: Hematology 1997, The Education Program of the American Society of Hematology, 1997; 158–65.

    Google Scholar 

  52. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525–33.

    Article  PubMed  CAS  Google Scholar 

  53. Williams CD, Goldstone AH, Pearce RM, et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin’s lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454–64.

    PubMed  CAS  Google Scholar 

  54. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–4.

    Article  PubMed  CAS  Google Scholar 

  55. Yuen AR, Rosenberg SA, Hoppe RT, et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease. Blood 1997; 89: 814–22.

    PubMed  CAS  Google Scholar 

  56. Hasenclever D, Diehl V. A numerical index to predict tumor control in advanced Hodgkin’s disease (abstract). Blood 1996; 88 (Suppl. 1): 673a.

    Google Scholar 

  57. Carella AM. The place of high-dose therapy with autologous stem cell transplantation in primary treatment of Hodgkin’s disease. Ann Oncol 1993; 4 (Suppl. 1): 15–19.

    Article  PubMed  Google Scholar 

  58. Forman SJ. Role of high-dose therapy and stem-cell transplantation in the management of Hodgkin’s disease. In: ASCO Education Book, Spring 1997; 244–7.

    Google Scholar 

  59. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroups Français du Myelome. N Engl J Med 1996; 335: 91–7.

    Article  PubMed  CAS  Google Scholar 

  60. Vescio R, Stewart A, Ballester O, et al. Myeloma cell tumor reduction in PBPC autografts following CD34 selection: the results of a phase III trial using the CEPRATE device (abstract). Blood 1997; 90 (Suppl. 1): 421a.

    Google Scholar 

  61. Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711–18.

    PubMed  CAS  Google Scholar 

  62. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345: 1016–20.

    Article  PubMed  CAS  Google Scholar 

  63. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662–70.

    PubMed  CAS  Google Scholar 

  64. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483–9.

    PubMed  CAS  Google Scholar 

  65. Stadtmauer EA, O’Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1069–76.

    Article  PubMed  CAS  Google Scholar 

  66. Peters W, Rosner G, Vredenburgh J, et al. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 (abstract). Proc Am Soc Clin Oncol 1999; 18: 1a.

    Google Scholar 

  67. The Scandinavian Breast Cancer Study Group 9401. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored EEC therapy (abstract). Proc Am Soc Clin Oncol 1999; 18: 2a.

    Google Scholar 

  68. Hortobagyi GN, Buzdar AU, Champlin R, et al. Lack of efficacy of adjuvant high-dose (HD) tandem combination chemotherapy (CT) for high-risk primary breast cancer (HRPBC): a randomized trial (abstract). Proc Am Soc Clin Oncol 1998; 17: 123a.

    Google Scholar 

  69. Rodenhuis S, Richel DJ, van der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998; 352: 515–21.

    Article  PubMed  CAS  Google Scholar 

  70. Bezwoda WR. Randomised, controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer (abstract). Proc Am Soc Clin Oncol 1999; 18: 2a.

    Google Scholar 

  71. Weiss RB, Rifkin RM, Stewart FM, et al. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet 2000; 355: 999–1003.

    Article  PubMed  CAS  Google Scholar 

  72. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870–9.

    PubMed  CAS  Google Scholar 

  73. Lazarus HM. Hematopoietic progenitor cell transplantation in breast cancer: current status and future directions. Cancer Invest 1998; 16: 102–26.

    Article  PubMed  CAS  Google Scholar 

  74. Legros M, Dauplat J, Fleury J, et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III or IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302–8.

    PubMed  CAS  Google Scholar 

  75. Stiff PJ, Bayer R, Kerger C, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309–17.

    PubMed  CAS  Google Scholar 

  76. Motzer RJ, Mazumdar M, Bajorin DF, et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997; 15: 2546–52.

    PubMed  CAS  Google Scholar 

  77. Chevreau C, Droz JP, Pico JL, et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Eur Urol 1993; 23: 213–18.

    PubMed  CAS  Google Scholar 

  78. Elias AD, Ayash L, Frei E III, et al. Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst 1993; 85: 559–66.

    Article  PubMed  CAS  Google Scholar 

  79. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5: 1864–73.

    PubMed  CAS  Google Scholar 

  80. Meisenberg B. High-dose chemotherapy and autologous stem cell support for patients with malignant melanoma. Bone Marrow Transplant 1996; 17: 903–6.

    PubMed  CAS  Google Scholar 

  81. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341: 1165–73.

    Article  PubMed  CAS  Google Scholar 

  82. Koscielniak E, Klingebiel TH, Peters C, et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997; 19: 227–31.

    Article  PubMed  CAS  Google Scholar 

  83. Stewart DA, Gyonyor E, Paterson AHG, et al. High-dose melphalan ± total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing’s sarcoma or peripheral neuroectodermal tumor. Bone Marrow Transplant 1996; 18: 315–18.

    PubMed  CAS  Google Scholar 

  84. Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in children with high-risk Ewing’s tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995; 15: 697–705.

    PubMed  CAS  Google Scholar 

  85. Horowitz ME, Kinsella TJ, Wexler LH, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing’s sarcoma and rhabdomyosarcoma. J Clin Oncol 1993; 11: 1911–18.

    PubMed  CAS  Google Scholar 

  86. Storb R, Weiden PL, Sullivan KM, et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood 1987; 70: 116–21.

    PubMed  CAS  Google Scholar 

  87. Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941–9.

    PubMed  CAS  Google Scholar 

  88. Storb R, Leisenring W, Deeg HJ, et al. Long-term follow-up of a randomized trial of graft-versus-host disease preven-tion by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia (letter). Blood 1994; 83: 2749–56.

    PubMed  CAS  Google Scholar 

  89. Storb R. Bone marrow transplantation for aplastic anemia. Cell Transplant 1993; 2: 365–79.

    PubMed  CAS  Google Scholar 

  90. Passweg JR, Socié G, Hinterberger W, et al. Bone marrow transplantation for severe aplastic anemia: Has outcome improved? Blood 1997; 90: 858–64.

    PubMed  CAS  Google Scholar 

  91. Burt RK. BMT for severe autoimmune diseases: an idea whose time has come. Oncology (Huntington) 1997; 11: 1001–14.

    CAS  Google Scholar 

  92. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322: 417–21.

    Article  PubMed  CAS  Google Scholar 

  93. Walters MC, Patience M, Leisenring W, et al. Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. Biol Blood Marrow Transplant 1997; 3: 310–15.

    PubMed  CAS  Google Scholar 

  94. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versusleukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–62.

    PubMed  CAS  Google Scholar 

  95. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versusleukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–50.

    PubMed  CAS  Google Scholar 

  96. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–44.

    PubMed  Google Scholar 

  97. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337–43.

    PubMed  CAS  Google Scholar 

Further Reading

  • Armitage JO, Antman KH (eds) High-dose cancer therapy. Pharmacology, hematopoietins, stem cells, 2nd edn. Baltimore: Williams & Wilkins, 1995.

    Google Scholar 

  • Barrett AJ. Mechanisms of the graft-versus-leukemia reaction. Stem Cells 1997; 15: 248–58.

    Article  PubMed  CAS  Google Scholar 

  • Burt RK, Deeg HJ, Lothian ST, et al. (eds) Bone marrow trans-plantation. Austin, Texas: Landes Bioscience, 1998.

    Google Scholar 

  • Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 1997; 9: 139–45.

    Article  PubMed  CAS  Google Scholar 

  • Marcellus DC, Vogelsang GB. Graft-versus-host disease. Curr Opin Oncol 1997; 9: 131–8.

    Article  PubMed  CAS  Google Scholar 

  • Nikolic B, Sykes M. Bone marrow chimerism and transplantation tolerance. Curr Opin Immunol 1997; 9: 634–40.

    Article  PubMed  CAS  Google Scholar 

  • Ringden O. Allogeneic bone marrow transplantation for hematological malignancies–controversies and recent advances. Acta Oncol 1997; 36: 549–64.

    Article  PubMed  CAS  Google Scholar 

  • Vesole DH, Jagannath S, Tricot G, et al. Autologous bone marrow and peripheral blood stem cell transplantation in multiple myeloma. Cancer Invest 1996; 14: 378–91.

    Article  PubMed  CAS  Google Scholar 

  • Winter JN (editor) Blood stem cell transplantation. Boston: Kluwer Academic Publishers, 1997.

    Google Scholar 

Download references

Authors
  1. Mark R. Litzow
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. St Mary’s Hospital, Praed Street, W2 1NY, London, UK

    Nadey S. Hakim MD, PhD, FRCS, FRCSI, FACS, FICS (Consultant General and Transplant Surgeon, Surgical Director Transplant Unit) (Consultant General and Transplant Surgeon, Surgical Director Transplant Unit)

  2. Kidney & Pancreas Transplant Programs, BH-427 Center for the Health Sciences, UCLA School of Medicine, Box 951796, 90095-1796, Los Angeles, CA, USA

    Gabriel M. Danovitch MD (Professor of Medicine) (Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag London

About this chapter

Cite this chapter

Litzow, M.R. (2001). Blood and Marrow Transplantation. In: Hakim, N.S., Danovitch, G.M. (eds) Transplantation Surgery. Springer Specialist Surgery Series. Springer, London. https://doi.org/10.1007/978-1-4471-3689-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-3689-7_14

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84996-859-1

  • Online ISBN: 978-1-4471-3689-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation